M. Lazzeri et al., KIDNEYS DERIVED FROM MICE TRANSGENIC FOR HUMAN-COMPLEMENT BLOCKERS ARE PROTECTED IN AN IN-VIVO MODEL OF HYPERACUTE REJECTION, The Journal of urology, 159(4), 1998, pp. 1364-1369
Purpose: The major obstacle to successful discordant kidney xenotransp
lantation is hyperacute rejection (HAR). Complement plays a key role i
n the induction of HRA, defined by endothelial cell activation, loss o
f vascular integrity, hemorrhage and thrombosis. The activation of com
plement is tightly controlled by a number of species-specific regulato
ry proteins which inhibit, at different points, the cascade of events
leading to the formation of the membrane attack complex (MAC). We have
tested the hypothesis that kidneys derived from transgenic mice expre
ssing two human complement inhibitors, Decay Accelerating Factor (hDAF
) and Membrane Cofactor Protein (MCP), could be protected from human c
omplement-mediated damage. Materials and Methods: Control and transgen
ic mice were perfused with human plasma by cannulation of the right ju
gular vein, at a perfusion rate of 10 mu L./min. for two hours. Comple
ment C3 deposition was detected on kidney sections by immunohistochemi
stry using specific FITC antibody. Complement-induced tissue damage wa
s evaluated by histopathological examination. Results: Heavy depositio
n of complement C3 was observed on kidneys derived from perfused contr
ol mice. This was associated with a characteristic HAR pathology of se
vere interstitial hemorrhage, inflammatory reaction, loss of glomerula
and tubuli structure. Kidneys derived from mice transgenic for hDAF o
r hMCP were partially protected from both complement C3 deposition and
tissue damage. The expression of both hDAF and hMCP in double transge
nic mice significantly increases the protection from human complement-
mediated damage. Conclusion: A novel model of in vivo perfusion with h
uman plasma has been adopted to recreate the initial event of HAR. Our
data show that this murine model could be very valuable to determine
the effect of transgenic human molecules in protecting vascularized or
gans from human complement attack.